Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin

References

• Iseki K, Ikemiya Y, Iseki C, Takishita S. Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant. 2003;18:899–905.
   PubMed Web of Science ®Google Scholar
• Nangaku M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17–25.
   PubMed Web of Science ®Google Scholar
• Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet. 2005;365:1890–1892.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–185.
   PubMed Web of Science ®Google Scholar
• Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66:753–760.
   PubMed Web of Science ®Google Scholar
• Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66:1131–1138.
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
   PubMed Web of Science ®Google Scholar
• Tsubakihara Y, Gejyo F, Nishi S, et al. High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients. Ther Apher Dial. 2012;16:529–540.
   PubMed Web of Science ®Google Scholar
• Tsubakihara Y, Nishi S, Akiba T, et al. 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010;14:240–275.
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–992.
   PubMed Web of Science ®Google Scholar
• Tsubakihara Y, Akizawa T, Iwasaki M, et al. High hemoglobin levels maintained by an erythropoiesis-stimulating agent improve renal survival in patients with severe renal impairment. Ther Apher Dial. 2015;19:457–465.
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens. 2009;18:15–20.
   PubMed Web of Science ®Google Scholar
• Kitamura H, Isaka Y, Takabatake Y, et al. Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant. 2008;23:1521–1528.
   PubMed Web of Science ®Google Scholar
• Yokomaku Y, Sugimoto T, Kume S, et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol. 2008;19:321–328.
   PubMed Web of Science ®Google Scholar
• Cassis P, Gallon L, Benigni A, et al. Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int. 2012;81:903–918.
   PubMed Web of Science ®Google Scholar
• Oba S, Suzuki E, Nishimatsu H, et al. Renoprotective effect of erythropoietin in ischemia/reperfusion injury: Possible roles of the Akt/endothelial nitric oxide synthase-dependent pathway. Int J Urol. 2012;19:248–255.
   PubMed Web of Science ®Google Scholar
• Coldewey SM, Khan AI, Kapoor A, et al. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β-common receptor. Kidney Int. 2013;84:482–490.
   PubMed Web of Science ®Google Scholar
• Aizawa K, Takeda S, Tashiro Y, et al. Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome. Am J Nephrol. 2012;36:419–426.
   PubMed Web of Science ®Google Scholar
• Toba H, Sawai N, Morishita M, et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol. 2009;612:106–114.
   PubMed Web of Science ®Google Scholar
• Dang J, Jia R, Tu Y, Xiao S, Ding G. Erythropoietin prevents reactive oxygen species generation and renal tubular cell apoptosis at high glucose level. Biomed Pharmacother. 2010;64:681–685.
   PubMed Web of Science ®Google Scholar
• Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M. Antioxidative effects of erythropoietin. Kidney Int Suppl. 2007;107:S10–S15.
   PubMed Web of Science ®Google Scholar
• Lee SH, Li C, Lim SW, et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol. 2005;25:64–76.
   PubMedGoogle Scholar
• Chang YK, Choi DE, Na KR, et al. Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects. J Urol. 2009;181:1434–1443.
   PubMed Web of Science ®Google Scholar
• Srisawat N, Manotham K, Eiam-Ong S, Katavetin P, Praditpornsilpa K, Eiam-Ong S. Erythropoietin and its non-erythropoietic derivative: Do they ameliorate renal tubulointerstitial injury in ureteral obstruction? Int J Urol. 2008;15:1011–1017.
   PubMed Web of Science ®Google Scholar
• Park SH, Choi MJ, Song IK, et al. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: Role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol. 2007;18:1497–1507.
   PubMed Web of Science ®Google Scholar
• Aizawa K, Tashiro Y, Hirata M, Takeda S, Kawasaki R, Endo K. Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats. J Nephrol. 2014;7:395–401.
   Web of Science ®Google Scholar
• Kang DH, Park EY, Yu ES, Lee YS, Yoon KI. Renoprotective effect of erythropoietin (EPO): Possibly via an amelioration of renal hypoxia with stimulation of angiogenesis in the kidney. Kidney Int. 2005;67:1683
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64:1648–1652.
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110:1006–1012.
   PubMed Web of Science ®Google Scholar
• Eto N, Wada T, Inagi R, et al. Podocyte protection by darbepoetin: Preservation of the cytoskeleton and nephrin expression. Kidney Int. 2007;72:455–463.
   PubMed Web of Science ®Google Scholar
• Imai E, Yamamoto R, Suzuki H, Watanabe T. Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin Exp Nephrol. 2010;14:445–452.
   PubMed Web of Science ®Google Scholar
• Furumatsu Y, Nagasawa Y, Hamano T, et al. Integrated therapies including erythropoietin decrease the incidence of dialysis: Lessons from mapping the incidence of end-stage renal disease in Japan. Nephrol Dial Transplant. 2008;23:984–990.
   PubMed Web of Science ®Google Scholar
• Choukroun G, Kamar N, Dussol B, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23:360–368.
   PubMed Web of Science ®Google Scholar